Business Description
Neuphoria Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US64136E1029
Share Class Description:
NEUP: Ordinary SharesTotal Employee Number:
8Description
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 571.79 | |||||
Equity-to-Asset | 0.85 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -6.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1589.3 | |||||
3-Year EBITDA Growth Rate | 7 | |||||
3-Year EPS without NRI Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | 591.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -93.36 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.01 | |||||
9-Day RSI | 54.61 | |||||
14-Day RSI | 51.12 | |||||
3-1 Month Momentum % | -27.8 | |||||
6-1 Month Momentum % | -15.89 | |||||
12-1 Month Momentum % | -57.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.31 | |||||
Quick Ratio | 14.31 | |||||
Cash Ratio | 12.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 88.7 | |||||
Shareholder Yield % | -84.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 112784.62 | |||||
Net Margin % | 134092.31 | |||||
EBITDA Margin % | 107692.31 | |||||
FCF Margin % | 131938.46 | |||||
OCF Margin % | 131938.46 | |||||
ROE % | -74.73 | |||||
ROA % | -55.15 | |||||
ROIC % | -104.8 | |||||
3-Year ROIIC % | -229.34 | |||||
ROC (Joel Greenblatt) % | -12694.37 | |||||
ROCE % | -51.24 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.73 | |||||
Price-to-Tangible-Book | 1.32 | |||||
EV-to-EBIT | -0.15 | |||||
EV-to-Forward-EBIT | -0.08 | |||||
EV-to-EBITDA | -0.16 | |||||
EV-to-Forward-EBITDA | -0.08 | |||||
EV-to-Revenue | -168.15 | |||||
EV-to-Forward-Revenue | 0.02 | |||||
EV-to-FCF | -0.13 | |||||
| Price-to-Net-Current-Asset-Value | 1.32 | |||||
| Price-to-Net-Cash | 1.53 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -79.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NEUP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neuphoria Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -0.013 | ||
| EPS (TTM) ($) | -11.06 | ||
| Beta | 0.6911 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 86.4 | ||
| 14-Day RSI | 51.12 | ||
| 14-Day ATR ($) | 0.205952 | ||
| 20-Day SMA ($) | 3.8015 | ||
| 12-1 Month Momentum % | -57.84 | ||
| 52-Week Range ($) | 3.19 - 21.4004 | ||
| Shares Outstanding (Mil) | 5.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuphoria Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuphoria Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-17 | In 183 days | ||
| General meeting for 2026 | 2026-12-09 10:00 | In 114 days | ||
| First quarter earnings results for 2026 | 2026-11-13 | In 87 days | ||
| Annual report for 2026 | 2026-09-29 | In 42 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-29 | In 42 days | ||
| Third quarter earnings results for 2026 | 2026-05-15 | 5.09 (+2.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-17 | 4.05 (+1.50%) | ||
| General meeting for 2025 | 2025-12-11 16:30 | 4.21 (-8.68%) | ||
| General meeting for 2025 | 2025-12-09 10:00 | 4.54 (+4.85%) | ||
| First quarter earnings results for 2025 | 2025-11-14 | 4.75 (-2.46%) |
Show
Entries
Neuphoria Therapeutics Inc Frequently Asked Questions
What is Neuphoria Therapeutics Inc(NEUP)'s stock price today?
The current price of NEUP is $4.00. The 52 week high of NEUP is $21.40 and 52 week low is $3.19.
When is next earnings date of Neuphoria Therapeutics Inc(NEUP)?
The next earnings date of Neuphoria Therapeutics Inc(NEUP) is 2026-09-29 Est..
Does Neuphoria Therapeutics Inc(NEUP) pay dividends? If so, how much?
Neuphoria Therapeutics Inc(NEUP) does not pay dividend.
Guru Commentaries on NAS:NEUP
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers